Vaccination with Adjuvants, Peptides and Elimination of Regulatory Cells: Enhancement of the body's anticancer immunity by vaccinatio

Phase 1

Completed

• Conditions: Advanced cancer; Cancer; Malignant neoplasm, unspecified

• Registration Number: ISRCTN07292674
• Lead Sponsor: ottingham University Hospitals NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-29
• Last Update Posted: 30 April 2018
• Study Completion: 2018-12-31

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age 18-85, either sex
2. Histologically or cytologically proven cancer
3. No further beneficial anticancer therapy available
4. Completed treatment at least 4 weeks previously
5. Post menopausal or sterilised or practising contraception
6. WHO status 3 or less
7. Life expectancy at least 30 weeks
8. Ability to give informed written consent

Exclusion Criteria

1. Pregnancy, lactation
2. Men and premenopausal women unwilling to practise reliable contraception
3. Inability to give informed written consent
4. Cerebral metastasis
5. Autoimmune disorders
6. Undergoing immunosuppressive therapy
7. Cardiovascular disease:coronary artery disease,major cardiac disease [left ventricular ejection fraction (LVEF <50%)], poorly controlled hypertension
8.Peptic ulceration,inflammatory bowel disease
9. Allergy to nonsteroidal anti-inflammatory drug (NSAID) therapy, celecoxib, asthma or allergy following aspirin
10. Allergy to sulphonamides
11. Past history of stroke or transient ischaemic attacks

Study & Design

• Study Type: Interventional
• Study Design: Not specified